Compare KeyCorp (KEY) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KeyCorp vs Zoetis Inc — how do they compare? KeyCorp trades at $23.16 (market cap $25.17B), while Zoetis Inc trades at $76.1 (market cap $31.95B). The key difference: Zoetis Inc is the larger of the two by market cap, and KeyCorp pays the higher dividend (3.52%). Which is the better fit depends on your goals.
| KEY | ZTS | |
|---|---|---|
Market Cap | $25.17B | $31.95B |
Sector | Financials | Health |
52-Week High | $23.99 | $156.76 |
52-Week Low | $16.78 | $71.91 |
Dividend Yield | 3.52% | 2.78% |
Enterprise Value | — | $39.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $23.26, down 1.23% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Strong fundamentals include a 26.05% net income margin and 10.61% ROE, while valuation metrics show a P/E of 14.45 and P/B of 1.45. Recent corporate actions include consistent quarterly dividends of $0.21 per share and a new $3 billion buyback program announced in July 2026.
KEY presents a compelling investment case with analyst consensus pointing to significant upside (price target $30.50, 31% potential). The combination of earnings momentum, shareholder-friendly capital returns, and improving loan growth supports bullish sentiment. However, risks include potential pressure on net interest margins from Fed policy and competitive challenges in regional banking. The stock's current valuation appears reasonable relative to earnings growth prospects.
Zoetis (ZTS) trades at $76.05, down 0.67% on the day, with a neutral technical signal and bearish moving averages. The company maintains strong fundamentals with a 28.03% net income margin and 67.75% ROE, though Q1 2026 earnings missed expectations. Recent news highlights multiple securities class action lawsuits filed against the company, creating near-term uncertainty despite the launch of new product Lenivia in Canada and EU markets.
The stock presents a mixed outlook with attractive valuation metrics (P/E 12.55) and analyst consensus price target of $101.43 suggesting 33% upside potential. However, legal challenges and the recent earnings miss pose significant near-term risks. Institutional sentiment remains divided with 47% buy ratings versus 53% hold ratings, indicating cautious optimism amid legal headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
